MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 197 filers reported holding MYRIAD GENETICS INC in Q1 2021. The put-call ratio across all filers is 0.68 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $584,913 | -37.0% | 40,311 | -17.2% | 0.01% | -43.8% |
| Q3 2022 | $929,000 | +8.8% | 48,685 | +3.6% | 0.02% | +14.3% |
| Q2 2022 | $854,000 | -32.2% | 46,991 | -6.0% | 0.01% | -22.2% |
| Q1 2022 | $1,259,000 | -7.4% | 49,977 | +1.4% | 0.02% | 0.0% |
| Q4 2021 | $1,360,000 | -16.8% | 49,290 | -2.6% | 0.02% | -21.7% |
| Q3 2021 | $1,634,000 | +6.0% | 50,619 | +0.5% | 0.02% | +4.5% |
| Q2 2021 | $1,541,000 | -17.9% | 50,386 | -18.3% | 0.02% | -24.1% |
| Q1 2021 | $1,878,000 | +70.3% | 61,669 | +10.6% | 0.03% | +61.1% |
| Q4 2020 | $1,103,000 | +80.2% | 55,780 | +18.9% | 0.02% | +50.0% |
| Q3 2020 | $612,000 | +11.5% | 46,914 | -3.0% | 0.01% | +9.1% |
| Q2 2020 | $549,000 | -22.8% | 48,388 | -2.6% | 0.01% | -35.3% |
| Q1 2020 | $711,000 | -45.0% | 49,667 | +4.6% | 0.02% | -37.0% |
| Q4 2019 | $1,293,000 | -12.5% | 47,499 | -8.0% | 0.03% | -18.2% |
| Q3 2019 | $1,478,000 | – | 51,610 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 5,000,000 | $90,850,000 | 3.94% |
| Altium Capital Management LP | 221,000 | $4,016,000 | 1.61% |
| DISCIPLINED GROWTH INVESTORS INC /MN | 1,900,787 | $34,537,000 | 0.93% |
| Zebra Capital Management LLC | 15,352 | $279,000 | 0.82% |
| PFM Health Sciences, LP | 1,177,250 | $21,391,000 | 0.82% |
| EARNEST PARTNERS LLC | 6,462,138 | $117,417,000 | 0.78% |
| Glenview Capital Management | 1,696,791 | $30,831,000 | 0.77% |
| AIMZ Investment Advisors, LLC | 42,085 | $765,000 | 0.37% |
| Phocas Financial Corp. | 127,949 | $2,325,000 | 0.35% |
| Redhawk Wealth Advisors, Inc. | 34,680 | $630,000 | 0.29% |